A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)

• Lionel Ades,
• Agnès Guerci-Bresler,
• Pascale Cony-Makhoul,
• Laurence Legros,
• Marie Sebert,
• Thorsten Braun,
• Jacques Delaunay,
• Kristell Desseaux,
• Sylvie Chevret,
• Pierre Fenaux

Affiliations

Lionel Ades

Service d’Hématologie Séniors, St Louis Hospital, University Paris 7

Agnès Guerci-Bresler

Hematology Department, Hopital d’Adultes du Brabois, Nancy

Pascale Cony-Makhoul

Centre Hospitalier d’Annecy

Laurence Legros

Hematology Department, CH de l’Archet, Nice

Marie Sebert

Service d’Hématologie Séniors, St Louis Hospital, University Paris 7

Thorsten Braun

Hematologie Clinique, CHU Avicenne, Bobigny

Jacques Delaunay

Department of Hematology, Nantes University Hospital

Kristell Desseaux

Department of Statistics (DBIM), Hôpital Saint Louis University Paris 7, France

Sylvie Chevret

Department of Statistics (DBIM), Hôpital Saint Louis University Paris 7, France

Pierre Fenaux

Service d’Hématologie Séniors, St Louis Hospital, University Paris 7